Loading... please wait

Concordia is partnering with Lazarex Cancer Foundation, a non-profit focused on improving patient access to cancer clinical trials, with the ultimate goal of ensuring that patients are able to undergo the most advanced and innovative cancer treatments.

This year-round programming partnership will provide a platform to spread awareness about the importance of—and barriers to—expanding patient access to clinical trials through increased participation, minority enrollment, and retention. It will also engage a multi-sector audience, including key stakeholders and policy makers, to ensure a continued commitment to finding sustainable solutions to accelerating cancer research.

At Concordia, our Global Health & Emergency Response Programming Pipeline focuses on issues ranging from international epidemics and equitable health access to global aid delivery and natural disaster preparedness. Within this pipeline, a key issue for our Members, Advisors, and Partners is the need to advance collaborative cancer research.

Making cancer treatments accessible and affordable remains one of the biggest challenges of today. Lazarex’s work to create an even playing field for all patients has resulted in the FDA issuing official guidance earlier this year to reimburse patients for travel expenses relating to clinical trials, therefore allowing all cancer patients access to potentially life-saving treatments.

While this new FDA guidance opens the door to new pathways and discussions, it is critical that all actors have a seat at the table in order to establish collaborative, lasting solutions. With this in mind, Concordia’s programming partnership with Lazarex will look to bring together thought leaders in oncology and healthcare to spark critical discussions around the outlook for cancer treatment across the world. Convening lawmakers, government representatives, and pharmaceutical companies, we will explore how to prompt policy and action to increase clinical trial participation and improve cancer survivability rates, regardless of a patient’s ability to pay.

To learn more about Lazarex, please visit Lazarex.org

To learn more about the 2018 Concordia Annual Summit, please visit https://www.concordia.net/annualsummit/2018annualsummit/


“We are thrilled about the opportunity this partnership with Concordia brings. It not only creates greater possibilities for meaningful collaboration with public and private partners, but it also sets the stage for substantive action on one of the greatest barriers to healthcare cancer patients face in this country,”

Dana Dornsife, Chairman of the Board & President of Lazarex Cancer Foundation

“Our partnership with Concordia comes at a critical moment. We are developing meaningful programs to provide all cancer patients equitable access to advanced treatments, but more must be done. We are hopeful our work with Concordia’s partners will create the consequential discussions and will give us the platform we need to make the most sustainable impact possible,”

Dana Dornsife, Chairman of the Board & President of Lazarex Cancer Foundation

“At Concordia, our Global Health & Emergency Response Programming Pipeline remains a key focus this year, and I am proud to announce that we will be partnering with Lazarex Cancer Foundation to advance collaborative solutions to cancer research and treatment,”

Matthew Swift, Co-Founder, Chairman & CEO of Concordia

“Cancer remains a critical challenge of our time, but one step towards progress is ensuring increased patient access to clinical trials. Lazarex is doing some fantastic work in this space, in terms of giving patients the opportunity to take advantage of the latest developments in cancer treatments, and I look forward to advancing conversations with them and exploring opportunities for cross-sector partnerships,”

Matthew Swift, Co-Founder, Chairman & CEO of Concordia